RSV candidate ready for phase I in success for Boston Children's Hospital and Danish researchers
The Danish State Serum Institute (SSI) has helped develop a candidate which has proved effective against the respiratory syncytial virus in mice – next up is human testing.
by ritzau, translated by daniel pedersen
A RSV vaccine candidate for newborns, which was developed in a collaboration between Boston Children’s Hospital and researchers from the Danish State Serum Institute, SSI, has reported promising results after testing with mice, the Danish vaccine authority writes in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
